Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis - Top-Institutions - MDSpire

Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis

  • By

  • Xinlong Xu

  • Chang Dong

  • Jiashuo Guo

  • Xiaolin Chang

  • Yu Zhang

  • Shuting Gou

  • Liying Xue

  • Jie Li

  • April 29, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Immunotherapy

  • #2

    University of Pennsylvania
    University of Pennsylvania

    Philadelphia, PA

    Key Differentiators

    • Hematology
    • Immunotherapy
    • Cellular Therapy

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Immunotherapy

  • #4

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Immunotherapy
    • Cellular Therapy

Original Source(s)

Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis

  • by Xinlong Xu, Chang Dong, Jiashuo Guo, Xiaolin Chang, Yu Zhang, Shuting Gou, Liying Xue, Jie Li

  • April 29, 2026

Related Content

Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation

Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship

Case Report: Acute myeloid leukemia with mixed immunophenotypic features and TCF3::ZNF384 fusion in a pediatric patient with CNS involvement: a diagnostic and therapeutic challenge